Non-Hodgkin lymphoma (NHL) is a condition where abnormal
lymphocytes are produced in the human body. These lymphocytes do not die and
keep growing and dividing within the body unless treated. NHL is generally
located at lymph nodes, however, if not treated in time then it might spread to
the entire lymphatic system.
Factors such as demand for innovative drugs and novel technologies,
FDA's approval for chronic lymphocytic leukemia therapy drugs, introduction of
promising drugs such as novel small molecule inhibitors and next-generation
monoclonal antibodies, and increase in prevalence of NHL drives the Non-Hodgkin Lymphoma
Therapeutics Market growth.
However, high cost of the vaccines used in NHL therapy and
side-effects associated with them restrain the market growth. Moreover,
introduction of newer biologics in the NHL market, patent expiry of standard
drugs in untapped market provide numerous opportunities regarding healthcare in
near future.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/4229
The key players in the market include Bristol Myers Squibb Co.,
Celgene Corp., Eli Lilly and Co., F. Hoffman La-Roche Ltd., GlaxoSmithKline plc,
Accredo Health Group Inc., Baxter International Inc., Bayer AG, Cephalon Inc.,
and Eisai Pharmaceuticals Inc.
The non-Hodgkin lymphoma therapeutics market is segmented on the
basis of therapy type, cell type, and region. Based on therapy type, it is bifurcated
into chemotherapy and targeted therapy. By cell type, it is divided into B-cell
lymphomas and T-cell lymphoma. By geography, it is analyzed across North
America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain,
and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea,
and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and
rest of LAMEA).
Key Benefits
- The study provides an in-depth
analysis of the market with current trends and future estimations to
elucidate the imminent investment pockets.
- Comprehensive analysis of all
geographical regions is provided to determine the prevailing
opportunities.
- Key players are profiled and their
strategies are analyzed thoroughly, which explains the competitive outlook
of the global market.
- The report offers a quantitative
analysis from 2016 to 2023 to enable the stakeholders to capitalize on the
prevailing market opportunities.
- Exhaustive analysis by type helps
understand the types of therapy used and the variants that are expected to
gain prominence in the future.
No comments:
Post a Comment